key: cord-1037669-8qdcls1k authors: Raw, R. K.; Kelly, C.; Rees, J.; Wroe, C.; Chadwick, D. R. title: Previous COVID-19 infection but not Long-COVID is associated with increased adverse events following BNT162b2/Pfizer vaccination date: 2021-04-22 journal: nan DOI: 10.1101/2021.04.15.21252192 sha: c38ade67ff3404d33612342fd5ccc76af7d58f79 doc_id: 1037669 cord_uid: 8qdcls1k Recent evidence suggests individuals with a history of COVID-19 are more likely to experience Adverse Events (AEs) following vaccination. A survey of 974 healthcare staff found that those with prior positive SARS-CoV-2 PCR and/or antibody results, reported more moderate/severe AEs, than those without past infection, particularly systemic symptoms, as did those with features of long COVID. with fever, fatigue, myalgia-arthralgia and lymphadenopathy significantly more common. There was no significant relationship between illness-vaccine interval and symptom composite score (r s =0.09, p=.44). Long-COVID was not associated with worse AEs in All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 4 comparison to the group without previous COVID-19. In the smaller sensitivity analysis cohort (412 people) similar findings were obtained although only myalgia and arthralgia remained significant. Prior COVID-19 infection but not ongoing Long-COVID symptoms were associated with an increase in the risk of self-reported adverse events following BNT162b2/Pfizer vaccination. COVID-19 illness-vaccination interval did not significantly influence AEs. This data can support education around vaccine-associated AEs and, through improved understanding, help to combat vaccine hesitancy. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 22, 2021. The BNT162b2/Pfizer and mRNA-1273/Moderna COVID-19 vaccines 1,2 were recently approved for use in the UK, with the former widely used amongst priority groups. While safety profiles were deemed acceptable (following phase 3 trials), participants with previous COVID-19 infection were excluded. Recent evidence suggests mRNA vaccines may cause more Adverse Events (AEs) in those with a history of COVID-19. [3] [4] [5] A small study found that AEs reported after the first dose of mRNA vaccine in seropositive individuals, were greater than in those with no prior COVID-19. 3 The 'ZOE COVID-19 Symptom Study' also observed similar outcomes via a self-reporting app. 4 Most recently in a larger study, 532 out of 2002 participants with prior COVID-19 reported increased (mostly systemic) AEs after either an mRNA or vector-based (AZD1222/AstraZeneca) vaccine. 5 These preliminary studies suggest a need for further investigation into the effect of prior COVID-19 history on vaccine-related AEs. Consideration of whether time between previous infection and vaccination administration or the presence of 'Long-COVID' [6] [7] [8] can predict AEs, is also warranted. This information is important, as it could assist in identifying individuals who are more likely to experience side effects to COVID-19 vaccines. Furthermore, there are public health implications with regards to vaccine hesitancy, which is somewhat driven by fear of AEs. [9] [10] [11] As part of a longitudinal observational study of COVID-19 in healthcare workers in North-East England, we evaluated AEs following first doses of BNT162b2/Pfizer vaccine, with particular reference to previous COVID-19 and Long-COVID. National Health Service (NHS) workers (employed by 3 North-East Trusts in the UK) completed an electronic survey on AEs following COVID-19 vaccination. The survey captured self-reported COVID-19 symptoms, PCR/antibody results, and AEs following the first dose. The FDA Toxicity Grading Scale 12 (with simplified language) was modified allowing participants to self-report AEs for severity (mild/moderate/severe/very severe), All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 22, 2021. ; https://doi.org/10.1101/2021.04.15.21252192 doi: medRxiv preprint 6 duration (≤24 hours/>24 hours) and onset (≤24 hours/>24 hours); lymphadenopathy was included as an additional symptom. A composite score for symptom nature and severity was calculated, to provide an overall estimate of AE-related morbidity, for the former by adding number of moderate/severe symptoms, and the latter by multiplying this by symptom duration. Individual and composite AE scores were compared between those with and without a prior history of COVID-19, as indicated by self-reported prior positive antibody and/or PCR result. Long-COVID was defined as symptoms persisting >2 months to vaccination. Effects of age, gender and time between past infection to vaccination were also considered. Respondents who had permitted laboratory results to be accessed (SARS-CoV-2 PCR and antibody), formed a subgroup for sensitivity analysis. Statistical analysis was carried out using JASP v0.14.1.0. Composite scores were compared using 2-way ANCOVA. Multivariable logistic regressions were performed to identify the relationship between COVID-19 status and the presence of moderate/severe symptoms in each category, and the Bonferroni correction applied to the resulting significance and confidence intervals. The study was approved by Cambridge East Research Ethics Committee. Of 974 healthcare workers (aged 19-72-years) responding to the survey and providing complete data for analysis, 265 (27%) participants (84% female, mean age 48.9) reported a prior positive PCR and/or antibody result, and 709 (80% female, mean age 47.0) had no COVID-19 history. Within the previous COVID-19 group (symptoms median 8.9 months All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 22, 2021. ; https://doi.org/10.1101/2021.04.15.21252192 doi: medRxiv preprint Symptom number and duration was not significantly higher in those with Long-COVID after accounting for gender and age effects and no individual symptom was significantly associated with this condition. Importantly, among those with prior COVID-19, there was no significant relationship between illness-vaccine time interval and either composite score This study of healthcare workers demonstrated that prior COVID-19 infection, but not Long-COVID, is associated with increased risk of AEs including lymphadenopathy following BNT162b2/Pfizer vaccination, although there was no relationship with duration since COVID-19 illness. Women and younger individuals were also more likely to experience vaccinerelated AEs. Our findings add to other reports supporting wider understanding of AEs following COVID-19 vaccination. [3] [4] [5] Importantly, given the hesitancy surrounding COVID-19 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. [9] [10] [11] our findings may help inform those with previous COVID-19, including Long-COVID, of increased susceptibility to certain AEs. Our study also adds weight to the question of whether a second dose of mRNA vaccine is necessary in those with previous COVID-19, assuming effective immunity is established after the first dose. 3, 14 This is relevant, given that another study has suggested worse AEs following the second dose. 5 Our study has several limitations. Firstly, some non-responder bias 13 is likely, with 27% of participants reporting previous COVID-19. This is slightly higher than in UK healthcare workers. 15 Nevertheless, the sample was broadly representative of UK healthcare employees and likely generalizable. Secondly, information on AEs was gathered via selfreported questionnaires, and hence subjective. Thirdly, PCR and antibody results were selfreported. We addressed this via a sensitivity analysis on a subset of participants with laboratory data available, which mostly confirmed the findings in the entire sample. Finally, the numbers with Long-COVID were relative small for comparison. In conclusion, this large study shows an association of previous COVID-19 with increased AEs and will help those with previous COVID-19 infection understand better what to expect following vaccination. DRC/CK/RKR conceived the study and DRC is chief investigator of CHOIS. RKR acted as site principal investigator. DRC/RKR/CW contributed to the study protocol, design, and data collection. JR/RKR/DRC did the statistical analysis. RKR/JR/DRC prepared the manuscript. All authors critically reviewed and approved the final version. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 22, 2021. ; https://doi.org/10.1101/2021.04.15.21252192 doi: medRxiv preprint No conflicts of interest. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine Robust spike antibody responses and increased reactogenicity in seropositive individuals after a 1 single dose of SARS-CoV-2 mRNA vaccine Kings College London COVID Symptom Study. Here's what we know so far about the after effects of the Pfizer COVID vaccine Self-reported real-world safety and reactogenicity of COVID-19 vaccines: An international vaccine-recipient survey Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients After Acute COVID-19 Long-COVID': a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19 Persistent symptoms after Covid-19: qualitative study of 114 "long Covid" patients and draft quality principles for services. BMC Vaccine hesitancy' among university students in Italy during the COVID-19 pandemic No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted Vaccine hesitancy: the next challenge in the fight against COVID-19 COVID-19 vaccine hesitancy among medical students Guidance for Industry Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials Assessing Response Rates and Nonresponse Bias in Web and Paper Surveys Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals SARS-CoV-2 seroprevalence and asymptomatic viral carriage in healthcare workers: a cross-sectional study No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted We would like to thank the CHOIS research team, John Rouse and the North East and North Cumbria NIHR for assistance with the survey. Funding for the CHOIS study is from the North East and North Cumbria Academic Health Sciences Network (AHSN) and Siemens Healthcare Ltd, who provided assays -but had no input into the study design. All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.